• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于人工智能的分析解读肺癌对免疫检查点抑制剂的反应和耐药性：PIONeeR 遇见 QUANTIC。

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.

机构信息

Centre de Recherche en Cancérologie de Marseille, SMARTc, Aix-Marseille Université, Inserm U1068, CNRS UMR 7258, Institut Paoli Calmettes, 13009, Marseille, France.

Assistance Publique Hôpitaux de Marseille, Marseille, France.

出版信息

Br J Cancer. 2020 Aug;123(3):337-338. doi: 10.1038/s41416-020-0918-3. Epub 2020 Jun 16.

DOI:10.1038/s41416-020-0918-3
PMID:32541872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7403333/
Abstract

This project aims to generate dense longitudinal data in lung cancer patients undergoing anti-PD1/PDL1 therapy. Mathematical modelling with mechanistic learning algorithms will help decipher the mechanisms underlying the response or resistance to immunotherapy. A better understanding of these mechanisms should help identifying actionable items to increase the efficacy of immune-checkpoint inhibitors.

摘要

本项目旨在生成接受抗 PD1/PDL1 治疗的肺癌患者的密集纵向数据。使用具有机械学习算法的数学模型将有助于破译免疫疗法反应或耐药的机制。更好地了解这些机制应有助于确定可操作的项目，以提高免疫检查点抑制剂的疗效。

相似文献

1
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.基于人工智能的分析解读肺癌对免疫检查点抑制剂的反应和耐药性：PIONeeR 遇见 QUANTIC。
Br J Cancer. 2020 Aug;123(3):337-338. doi: 10.1038/s41416-020-0918-3. Epub 2020 Jun 16.
2
Immunotherapy in non-small cell lung cancer harbouring driver mutations.携带驱动基因突变的非小细胞肺癌的免疫治疗
Cancer Treat Rev. 2021 May;96:102179. doi: 10.1016/j.ctrv.2021.102179. Epub 2021 Mar 19.
3
Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.肺癌辅助和新辅助免疫治疗的最新进展和未来展望。
Jpn J Clin Oncol. 2021 Jan 1;51(1):28-36. doi: 10.1093/jjco/hyaa187.
4
Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?肺癌的最佳一线免疫检查点抑制剂治疗：如何选择？
Future Oncol. 2022 Feb;18(6):635-638. doi: 10.2217/fon-2021-1348. Epub 2022 Jan 12.
5
The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.CTLA4 抑制剂联合 PD1/PDL1 抑制剂在 IIIB/IV 期非小细胞肺癌中的获益与风险：基于随机对照试验的系统分析和荟萃分析。
J Clin Pharm Ther. 2021 Dec;46(6):1519-1530. doi: 10.1111/jcpt.13465. Epub 2021 Jun 8.
6
Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.免疫检查点抑制剂治疗不同基因突变的非小细胞肺癌患者的疗效：一项荟萃分析。
Medicine (Baltimore). 2021 Mar 12;100(10):e19713. doi: 10.1097/MD.0000000000019713.
7
Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer.免疫检查点抑制剂治疗非小细胞肺癌的预测性遗传生物标志物。
Immunotherapy. 2022 Mar;14(4):249-257. doi: 10.2217/imt-2021-0175. Epub 2022 Jan 25.
8
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.免疫排斥常数作为预测免疫检查点抑制剂在非小细胞肺癌中的疗效的生物标志物。
J Transl Med. 2023 Sep 19;21(1):637. doi: 10.1186/s12967-023-04463-2.
9
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.针对非小细胞肺癌中罕见的驱动基因突变。
Trends Cancer. 2021 May;7(5):410-429. doi: 10.1016/j.trecan.2020.11.005. Epub 2020 Dec 9.
10
Efficacy of immune checkpoint inhibitor therapy in patients with fusion-positive non-small-cell lung cancer.免疫检查点抑制剂治疗融合阳性非小细胞肺癌患者的疗效。
Immunotherapy. 2021 Aug;13(11):893-904. doi: 10.2217/imt-2021-0035. Epub 2021 Jun 18.

引用本文的文献

1
A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.人工智能在肺癌临床应用的全面综述
Cancers (Basel). 2025 Mar 4;17(5):882. doi: 10.3390/cancers17050882.
2
Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis.肺癌中PD-1/PD-L1抑制剂免疫治疗的研究趋势与亮点：一项文献计量学分析
Discov Oncol. 2025 Mar 11;16(1):292. doi: 10.1007/s12672-025-02052-x.
3
Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.新辅助治疗后转移性乳腺癌的机器学习和机制建模。
PLoS Comput Biol. 2024 May 3;20(5):e1012088. doi: 10.1371/journal.pcbi.1012088. eCollection 2024 May.
4
Mathematical Modeling Support for Lung Cancer Therapy-A Short Review.肺癌治疗的数学建模支持——简要综述。
Int J Mol Sci. 2023 Sep 25;24(19):14516. doi: 10.3390/ijms241914516.
5
Opportunities and challenges of 5G network technology toward precision medicine.5G 网络技术向精准医学发展的机遇与挑战。
Clin Transl Sci. 2023 Nov;16(11):2078-2094. doi: 10.1111/cts.13640. Epub 2023 Sep 25.
6
Carbonic Anhydrase IX Suppression Shifts Partial Response to Checkpoint Inhibitors into Complete Tumor Eradication: Model-Based Investigation.碳酸酐酶 IX 抑制将部分反应转变为完全肿瘤消除的检查点抑制剂：基于模型的研究。
Int J Mol Sci. 2023 Jun 13;24(12):10068. doi: 10.3390/ijms241210068.
7
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8 T Cells.细胞内黏附分子-1 通过激活 CD8 T 细胞提高对免疫检查点抑制剂的反应性。
Adv Sci (Weinh). 2023 Jun;10(17):e2204378. doi: 10.1002/advs.202204378. Epub 2023 Apr 25.
8
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.将基于血液的PD-L1表达评估作为抗PD-(L)1免疫疗法生物标志物的挑战与不断演变的形势
Biomedicines. 2022 May 20;10(5):1181. doi: 10.3390/biomedicines10051181.
9
mRNA in cancer immunotherapy: beyond a source of antigen.mRNA 在癌症免疫疗法中的作用：不仅仅是抗原的来源。
Mol Cancer. 2021 Mar 3;20(1):48. doi: 10.1186/s12943-021-01329-3.

本文引用的文献

1
Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?免疫肿瘤学药物联合策略的机制性学习：模型指导设计能否帮助研究人员？
JCO Precis Oncol. 2020 Nov;4:486-491. doi: 10.1200/PO.19.00381.
2
Tumor mutational burden in lung cancer: a systematic literature review.肺癌中的肿瘤突变负荷：一项系统文献综述
Oncotarget. 2019 Nov 12;10(61):6604-6622. doi: 10.18632/oncotarget.27287.
3
Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess.组合免疫治疗策略：多数神明掷骰子，然命运弈棋局。
Ann Oncol. 2019 Nov 1;30(11):1690-1691. doi: 10.1093/annonc/mdz297.
4
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.一线免疫检查点抑制剂治疗晚期非小细胞肺癌：光速前行。
Lung Cancer. 2019 Aug;134:245-253. doi: 10.1016/j.lungcan.2019.06.007. Epub 2019 Jun 19.
5
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?免疫肿瘤时代的液体活检：它是否已经准备好供癌症患者常规使用？
Ann Oncol. 2019 Sep 1;30(9):1448-1459. doi: 10.1093/annonc/mdz196.
6
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.抗生素对晚期肾细胞癌和非小细胞肺癌患者免疫检查点抑制剂临床疗效的负相关作用。
Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.
7
Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.免疫检查点抑制剂在非小细胞肺癌（NSCLC）中的应用：特殊亚组人群方法和未解决的热点问题。
Cancer Treat Rev. 2018 Mar;64:21-29. doi: 10.1016/j.ctrv.2018.02.002. Epub 2018 Feb 8.
8
Computational oncology--mathematical modelling of drug regimens for precision medicine.计算肿瘤学——精准医学中药物方案的数学建模。
Nat Rev Clin Oncol. 2016 Apr;13(4):242-54. doi: 10.1038/nrclinonc.2015.204. Epub 2015 Nov 24.